MASSANO, DAVIDE
MASSANO, DAVIDE
SCIENZE DELLA SANITA' PUBBLICA E PEDIATRICHE
A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients.
2012-01-01 De Francia S; Massano D; Piccione FM; Pirro E; Racca S; Di Carlo F; Piga A.
Clinical relevance of deferasirox trough levels in β-thalassemia patients
2018-01-01 Allegra, Sarah; Massano, Davide; De Francia, Silvia; Longo, Filomena; Piccione, Francesca; Pirro, Elisa; Cusato, Jessica; D'Avolio, Antonio; Piga, Antonio
Deferasirox AUC efficacy cutoff and role of pharmacogenetics
2016-01-01 Allegra, S; Cusato, J; De Francia, S; Massano, D; Piga, A; D'Avolio, A
Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment
2016-01-01 Allegra, Sarah; De Francia, Silvia; Cusato, Jessica; Pirro, Elisa; Massano, Davide; Piga, Antonio; D'Avolio, Antonio
Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients
2017-01-01 Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; Pirro, Elisa; Massano, Davide; Piga, Antonio; D'Avolio, Antonio
Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia
2016-01-01 Allegra, Sarah; De Francia, Silvia; Longo, Filomena; Massano, Davide; Cusato, Jessica; Arduino, Arianna; Pirro, Elisa; Piga, Antonio; D'Avolio, Antonio
Deferiprone
2010-01-01 A. Piga; S. Roggero; I. Salussolia; D. Massano; M. Serra; F. Longo
Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children
2018-01-01 Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; Longo, Filomena; Pirro, Elisa; Massano, Davide; Piga, Antonio; D'Avolio, Antonio
Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children
2016-01-01 Sarah Allegra, Jessica Cusato, Silvia De Francia, Arianna Arduino, Filomena Longo, Davide Massano, Antonio Piga, Antonio D'Avolio
Influence of single-nucleotide polymorphisms on deferasirox C-trough levels and effectiveness
2014-01-01 Cusato, J; Allegra, S; Massano, D; De Francia, S; Piga, A; D'Avolio, A.
Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients
2018-01-01 Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; Longo, Filomena; Pirro, Elisa; Massano, Davide; Avataneo, Valeria; De Nicolò, Amedeo; Piga, Antonio; D'Avolio, Antonio
Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes
2018-01-01 Allegra, Sarah; Cusato, Jessica; DE FRANCIA, Silvia; Arduino, A; Longo, Filomena; Pirro, Elisa; Massano, Davide; DE NICOLO', Amedeo; Piga, Antonio Giulio; D'Avolio, Antonio
Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes
2016-01-01 Sarah Allegra, Silvia De Francia, Jessica Cusato, Arianna Arduino, Elisa Pirro, Davide Massano, Filomena Longo, Antonio Piga, Antonio D'Avolio.
Role of pharmacogenetics on deferasirox AUC and efficacy
2016-01-01 Cusato, Jessica; Allegra, Sarah; DE FRANCIA, Silvia; Massano, Davide; Piga, Antonio Giulio; D'Avolio, Antonio
The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients
2019-01-01 Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; Longo, Filomena; Pirro, Elisa; Massano, Davide; Avataneo, Valeria; De Nicolò, Amedeo; Piga, Antonio; D'Avolio, Antonio
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients. | 2012 | De Francia S; Massano D; Piccione FM; Pirro E; Racca S; Di Carlo F; Piga A. | |
| Clinical relevance of deferasirox trough levels in β-thalassemia patients | 2018 | Allegra, Sarah; Massano, Davide; De Francia, Silvia; Longo, Filomena; Piccione, Francesca; Pirro, Elisa; Cusato, Jessica; D'Avolio, Antonio; Piga, Antonio | |
| Deferasirox AUC efficacy cutoff and role of pharmacogenetics | 2016 | Allegra, S; Cusato, J; De Francia, S; Massano, D; Piga, A; D'Avolio, A | |
| Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment | 2016 | Allegra, Sarah; De Francia, Silvia; Cusato, Jessica; Pirro, Elisa; Massano, Davide; Piga, Antonio; D'Avolio, Antonio | |
| Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients | 2017 | Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; Pirro, Elisa; Massano, Davide; Piga, Antonio; D'Avolio, Antonio | |
| Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia | 2016 | Allegra, Sarah; De Francia, Silvia; Longo, Filomena; Massano, Davide; Cusato, Jessica; Arduino, Arianna; Pirro, Elisa; Piga, Antonio; D'Avolio, Antonio | |
| Deferiprone | 2010 | A. Piga; S. Roggero; I. Salussolia; D. Massano; M. Serra; F. Longo | |
| Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children | 2018 | Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; Longo, Filomena; Pirro, Elisa; Massano, Davide; Piga, Antonio; D'Avolio, Antonio | |
| Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children | 2016 | Sarah Allegra, Jessica Cusato, Silvia De Francia, Arianna Arduino, Filomena Longo, Davide Massano, Antonio Piga, Antonio D'Avolio | |
| Influence of single-nucleotide polymorphisms on deferasirox C-trough levels and effectiveness | 2014 | Cusato, J; Allegra, S; Massano, D; De Francia, S; Piga, A; D'Avolio, A. | |
| Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients | 2018 | Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; Longo, Filomena; Pirro, Elisa; Massano, Davide; Avataneo, Valeria; De Nicolò, Amedeo; Piga, Antonio; D'Avolio, Antonio | |
| Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes | 2018 | Allegra, Sarah; Cusato, Jessica; DE FRANCIA, Silvia; Arduino, A; Longo, Filomena; Pirro, Elisa; Massano, Davide; DE NICOLO', Amedeo; Piga, Antonio Giulio; D'Avolio, Antonio | |
| Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes | 2016 | Sarah Allegra, Silvia De Francia, Jessica Cusato, Arianna Arduino, Elisa Pirro, Davide Massano, Filomena Longo, Antonio Piga, Antonio D'Avolio. | |
| Role of pharmacogenetics on deferasirox AUC and efficacy | 2016 | Cusato, Jessica; Allegra, Sarah; DE FRANCIA, Silvia; Massano, Davide; Piga, Antonio Giulio; D'Avolio, Antonio | |
| The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients | 2019 | Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; Longo, Filomena; Pirro, Elisa; Massano, Davide; Avataneo, Valeria; De Nicolò, Amedeo; Piga, Antonio; D'Avolio, Antonio |